Discover
ANVS
Annovis Bio, Inc.
1.92
3700 x undefined
1400 x undefined
bid
ask
+
0.06
3.23%
2550 @ 06:05 AM
1.80 -0.12 (6.25%)
| Ytd | -44.51% | |
| 1y | -17.60% |
1.87
day range
1.96
1.54
52 week range
5.50
| Open | 1.88 | Prev Close | 1.86 | Low | 1.87 | High | 1.96 | Mkt Cap | 81.68M |
| Vol | 708.78K | Avg Vol | 1.23M | EPS | -1.71 | P/E | N/A | Forward P/E | -2.77 |
| Beta | 1.70 | Short Ratio | 6.21 | Inst. Own | 8.83% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 1.95 | 200-d Avg | 2.54 | 1yr Est | 34.80 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-08 | 2024-09 | -0.64 | -0.97 | -0.33 | -51.56% |
| 2024-08-14 | 2024-06 | -0.7 | N/A | N/A | N/A |
| 2024-08-14 | 2024-06 | -0.7 | -0.44 | 0.26 | 37.14% |
| 2024-05-13 | 2024-03 | -0.87 | N/A | N/A | N/A |
| 2024-05-13 | 2024-03 | -0.87 | -0.72 | 0.15 | 17.24% |
| 2024-03-29 | 2023-12 | -1.35 | -1.09 | 0.26 | 19.26% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-11 | D. Boral Capital | Upgrade | Buy | Buy |
| 2024-11-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-25 | Maxim Group | Upgrade | Hold | Buy |
| 2024-08-15 | EF Hutton | Upgrade | Buy | Buy |
| 2024-08-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-13 | EF Hutton | Upgrade | Buy |
Profile
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-11-19 | BRUCK CLAUDINE | Director | 7.57K | Stock Award(Grant) |
| 2023-11-19 | HAGOPIAN HENRY III | Chief Financial Officer | 1.82K | Stock Award(Grant) |
| 2023-11-19 | HOFFMAN MICHAEL B | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Award(Grant) |
| 2024-03-27 | MACCECCHINI MARIA-LUISA | Chief Executive Officer | 1.07M | Stock Gift |
| 2023-11-19 | MCCARTHY REID S. | Director | 8.13K | Stock Award(Grant) |
| 2023-11-19 | WHITE MARK K. | Director | 61.18K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Group Inc | 380.26K | 1.91M | 2.76% |
| 2024-09-29 | Blackrock Inc. | 101.50K | 508.49K | 0.74% |
| 2024-09-29 | Citadel Advisors Llc | 102.69K | 514.49K | 0.74% |
| 2024-09-29 | Geode Capital Management, LLC | 99.11K | 496.56K | 0.72% |
| 2024-09-29 | Group One Trading, L.P. | 52.77K | 264.36K | 0.38% |
| 2024-09-29 | Quest Partners LLC | 46.00K | 230.47K | 0.33% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 263.51K | 1.32M | 1.91% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 110.60K | 554.11K | 0.80% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 55.36K | 277.33K | 0.40% |
| 2024-09-29 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 21.00K | 105.21K | 0.15% |
| 2024-10-30 | iShares Micro Cap ETF | 18.95K | 94.91K | 0.14% |
| 2024-10-30 | Fidelity Total Market Index Fund | 17.94K | 89.90K | 0.13% |